Free tool · No account

Clinical trials for bladder cancer

Bladder cancer trials differ between early, non-muscle-invasive disease and advanced disease, with immunotherapy and antibody-drug conjugates prominent in the advanced setting.

396 recruiting trials. Showing a sample.

  • recruitingNANCT04368702

    CONFIRM: Magnetic Resonance Guided Radiation Therapy

    This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdia...

    Sponsored by Brigham and Women's HospitalFull details on ClinicalTrials.gov →
  • recruitingPhase 1, Phase 2NCT07421700

    Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

    This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The pur...

  • recruitingPhase 2NCT07061964

    Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

    This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy includes chemotherapy before surgery (neo...

    Sponsored by National Cancer Institute (NCI)Full details on ClinicalTrials.gov →
  • recruitingPhase 2NCT06161532

    Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

    Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments. Two drugs-sacituzumab govitecan (SG) and atezolizu...

    Sponsored by National Cancer Institute (NCI)Full details on ClinicalTrials.gov →
  • recruitingNCT05153694

    Infectious Complications After Cystectomy: A Prospective Observational Study

    Patients undergoing cystectomy for either oncological or non-oncological indications are prospectively enrolled following informed consent. This study design incorporates a comprehensive medical history, detailed prospective documentation of clinicopathological parameters, and...

    Sponsored by Ludwig-Maximilians - University of MunichFull details on ClinicalTrials.gov →
  • recruitingPhase 2NCT06638931

    Agnostic Therapy in Rare Solid Tumors

    The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), rega...

    Sponsored by Instituto do Cancer do Estado de São PauloFull details on ClinicalTrials.gov →
  • recruitingPhase 1, Phase 2NCT07278479

    Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

    Sponsored by Molecular Partners AGFull details on ClinicalTrials.gov →
  • recruitingNCT00872495

    Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer

    The purpose of this study is to determine if analysis of DNA and protein material found in urine will be useful in the detection of urothelial cancer of the bladder and kidney. This analysis may be helpful to determine if how a particular cancer will act regarding remission an...

  • recruitingPhase 2, Phase 3NCT06851663

    Trop2-targeted immunoPET Imaging of Solid Tumors

    This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagn...

    Sponsored by RenJi HospitalFull details on ClinicalTrials.gov →
  • recruitingNCT05080998

    Longitudinal Bladder Cancer Study for Tumour Recurrence

    Surveillance for recurrence of urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance. This is a p...

    Sponsored by Pacific Edge LimitedFull details on ClinicalTrials.gov →

Data from ClinicalTrials.gov, retrieved 2026-07-13. These are trials worth asking your care team about, not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.

Refine for your situation

Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.

Whatever you have: the diagnosis, a mutation if you know it, age, where you live.

Trials for other conditions

What we will never do with your records

This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.

We won't sell your data.
Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
We won't train AI models on your records.
Anthropic (whose Claude model powers KeptWell) is contractually prohibited from training on anything we send them, under a signed Business Associate Agreement.
We won't lock you in.
You can export everything in your circle as a ZIP at any time. Cancellation is one click.

Read the full data practices →

Common questions

Is this bladder cancer trial finder really free?
Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
Does showing up here mean the patient qualifies?
No. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
How current is this list?
The trials come directly from ClinicalTrials.gov and are refreshed daily. Each result links to the full, live study record, and the finder above always runs a fresh search when you use it.
What should I do with a trial that looks promising?
Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.

Found trials worth discussing? Keep them next to the records.

The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.

Get started

No password. We'll email you a sign-in link — it works whether you're new here or already have an account.